Pluristem Therapeutics Inc (PSTI)

1.72
0.02 1.10
NASDAQ : Health Care
Prev Close 1.74
Open 1.77
Day Low/High 1.71 / 1.77
52 Wk Low/High 0.71 / 2.18
Volume 114.68K
Avg Volume 169.50K
Exchange NASDAQ
Shares Outstanding 80.16M
Market Cap 135.47M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pluristem Participates In Radiation Injury Treatment Network Conference Co-sponsored By National Institutes Of Health's NIAID

Pluristem Participates In Radiation Injury Treatment Network Conference Co-sponsored By National Institutes Of Health's NIAID

Pluristem's PLX-R18 is being studied by NIAID for Acute Radiation Syndrome (ARS), and following pharmacodynamics, safety and efficacy trials, the company plans to initiate a pivotal study to gain approval for ARS via the FDA Animal Rule.

Pluristem Continues To Strengthen Its Position In Japan - Granted Two Key Cell Therapy Patents

Pluristem Continues To Strengthen Its Position In Japan - Granted Two Key Cell Therapy Patents

IP addresses both 3D growth of placental and fat cells and the use of placental cells grown with 3D technology for the treatment of hematopoietic disorders

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights And Clinical Development Update

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights And Clinical Development Update

Strong Balance Sheet, Two Active Clinical Development Programs in the U.S. Accelerated Pathways to Commercialization in Japan & Europe

Pluristem Therapeutics (PSTI) Stock Surges on FDA Orphan Drug Designation

Pluristem Therapeutics (PSTI) Stock Surges on FDA Orphan Drug Designation

Pluristem Therapeutics (PSTI) stock is popping in mid-morning trading on Thursday after the FDA granted an orphan drug designation to its preeclampsia treatment.

U.S. Food & Drug Administration Grants Orphan Drug Designation To Pluristem's PLX-PAD Cells For Treatment Of Severe Preeclampsia

U.S. Food & Drug Administration Grants Orphan Drug Designation To Pluristem's PLX-PAD Cells For Treatment Of Severe Preeclampsia

PLX Cells Were Demonstrated to be Safe for Both the Mother and Fetus and Improved Several Parameters of Preeclampsia in Several Animal Studies

Pluristem To Present At Phacilitate Cell & Gene Therapy World Conference In Washington DC On January 25-26, 2016

Pluristem To Present At Phacilitate Cell & Gene Therapy World Conference In Washington DC On January 25-26, 2016

Yaky Yanay to Deliver Two Presentations Regarding Accelerated Clinical Development Pathways in Europe and Japan

Pluristem Signs MOU For Collaboration With Fukushima Medical University To Study PLX-R18 In Acute Radiation Syndrome

Pluristem Signs MOU For Collaboration With Fukushima Medical University To Study PLX-R18 In Acute Radiation Syndrome

Effects of PLX-R18 Will Be Studied in the Lungs, Gastrointestinal Tract, Skin, and Bone Marrow Following Exposure to Catastrophic Levels of Radiation

Pluristem To Present New Data On PLX-R18 At American Society Of Hematology's Annual Meeting

Pluristem To Present New Data On PLX-R18 At American Society Of Hematology's Annual Meeting

Data Show the Mechanism of Action by Which PLX-R18 Treats Radiation-Induced Bone Marrow Damage

Pluristem To Participate In Three European Life Sciences Conferences In November

Pluristem To Participate In Three European Life Sciences Conferences In November

BioEurope 2015, EU Advanced Therapies Investor Day & Berlin Dialogue

Pluristem CEO Zami Aberman Elected To Board Of Directors Of The Alliance For Regenerative Medicine

Pluristem CEO Zami Aberman Elected To Board Of Directors Of The Alliance For Regenerative Medicine

ARM is the Preeminent Global Advocate for the Advancement of Regenerative Medicine

Pluristem And NIAID Met With U.S. FDA And Agreed On Development Plan For Initiation Of Pivotal Study Of PLX-R18 In The Treatment Of Acute Radiation Syndrome

Pluristem And NIAID Met With U.S. FDA And Agreed On Development Plan For Initiation Of Pivotal Study Of PLX-R18 In The Treatment Of Acute Radiation Syndrome

PLX-R18 for Use in Acute Radiation Syndrome (ARS) is Being Developed Under the Animal Rule Regulatory Pathway With the NIAID's Support